Omicron Variant: Booster dose of AstraZeneca effective in producing high antibodies against Omicron, study revealed

Posted on 13th Jan 2022 by rohit kumar

Omicron Variant: Coronavirus infection seems to be spreading rapidly around the world. Amidst the fear of the third wave of corona infection, the new variant of the coronavirus, Omicron, has put everyone in trouble. At present, in many countries, the third dose of the Covid vaccine being administered for the prevention of corona infection is being given as a booster dose. On which it has been revealed in many studies that the booster dose of the Covid vaccine is successful in preventing corona infection.

 

Meanwhile, the pharmaceutical company AstraZeneca on Thursday has given information about the preliminary data of a test done on its COVID-19 vaccine Vaxzevria. In which AstraZeneca reported that when the Vaxzevria COVID vaccine is being given as a third booster, it produces a higher antibody response against Omicron variants and others including beta, delta, alpha, and gamma. Still working.

 

At present, this has come to the fore from a study conducted by the University of Oxford. AstraZeneca developed the vaccine with researchers from the University of Oxford, and last month laboratory studies found that the third dose of Vaxazevaria was effective against the rapidly spreading new Omicron variant.

 

Andrew Pollard, head of the Oxford Vaccine Group, said: 'These important studies suggest that the third dose of Vaxgeveria, after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, can protect against COVID-19. Strongly boosts immunity.

 

Let us tell you that earlier in December a major British trial found that AstraZeneca's vaccine increased antibodies when given as a booster after initial vaccination with its vaccine or Pfizer, which is based on mRNA technology. However, the study concluded that the mRNA vaccines made by Pfizer and Moderna provided the greatest boost to antibodies when given as a booster dose.

Other news